Stay updated with breaking news from Kim Papp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 Deep and...
– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose –
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024....
Data from a phase 3 trial of CT-P43 in patients with moderate to severe plaque psoriasis offers additional insight into the comparative effects of the biosimilar relative to ustekinumab.
The Psoriasis Area and Severity Index, or PASI, was developed in the 1970s as a tool for assessing the severity of psoriatic lesions for the purpose...